BIOMAT Database Logo BIOMAT Database Logo

Hypersensitivity reactions to etoposide phosphate. 2014

Khrishanthne Sambasivan, and Sarah Mahmoud, and Arwa Kokache, and Michael Seckl, and Philip Savage
Department of Medical Oncology, Charing Cross Hospital, London, UK.

Etoposide phosphate is a prodrug of intravenous etoposide recommended for use in patients with demonstrated allergy to etoposide. We have previously published a case series comprising six patients who were successfully treated with etoposide phosphate following preceding etoposide hypersensitivity. In this new paper we now present the cases of two patients who had allergic reactions to both etoposide and etoposide phosphate. As such, we suggest that whilst most patients with etoposide hypersensitivity can safely be treated with etoposide phosphate, a small number are at risk of an additional allergic reaction to etoposide phosphate. Patients being treated for the first time with etoposide phosphate after etoposide allergy should receive their first dose under medical supervision.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009943 Organophosphorus Compounds Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS. Organophosphorus Compound,Organopyrophosphorus Compound,Organopyrophosphorus Compounds,Compound, Organophosphorus,Compound, Organopyrophosphorus,Compounds, Organophosphorus,Compounds, Organopyrophosphorus
D004342 Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally. Allergy, Drug,Hypersensitivity, Drug,Drug Allergy,Allergies, Drug,Drug Allergies,Drug Hypersensitivities,Hypersensitivities, Drug
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

Khrishanthne Sambasivan, and Sarah Mahmoud, and Arwa Kokache, and Michael Seckl, and Philip Savage
Hypersensitivity reactions to etoposide.
April 1996, The Annals of pharmacotherapy,
Khrishanthne Sambasivan, and Sarah Mahmoud, and Arwa Kokache, and Michael Seckl, and Philip Savage
Hypersensitivity reactions induced by etoposide.
January 1984, Cancer treatment reports,
Khrishanthne Sambasivan, and Sarah Mahmoud, and Arwa Kokache, and Michael Seckl, and Philip Savage
Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide.
January 2002, British journal of cancer,
Khrishanthne Sambasivan, and Sarah Mahmoud, and Arwa Kokache, and Michael Seckl, and Philip Savage
Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide.
August 1999, Pharmacotherapy,
Khrishanthne Sambasivan, and Sarah Mahmoud, and Arwa Kokache, and Michael Seckl, and Philip Savage
Hypersensitivity reactions from taxol and etoposide.
December 1993, Journal of the National Cancer Institute,
Khrishanthne Sambasivan, and Sarah Mahmoud, and Arwa Kokache, and Michael Seckl, and Philip Savage
Severe hypersensitivity reaction to etoposide phosphate: A case report.
September 2020, Clinical case reports,
Khrishanthne Sambasivan, and Sarah Mahmoud, and Arwa Kokache, and Michael Seckl, and Philip Savage
Etoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity.
January 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
Khrishanthne Sambasivan, and Sarah Mahmoud, and Arwa Kokache, and Michael Seckl, and Philip Savage
Successful Treatment with Etoposide Base after an Acute Hypersensitivity Reaction to Etoposide Phosphate.
March 2016, Pediatric blood & cancer,
Khrishanthne Sambasivan, and Sarah Mahmoud, and Arwa Kokache, and Michael Seckl, and Philip Savage
Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity.
March 2008, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
Khrishanthne Sambasivan, and Sarah Mahmoud, and Arwa Kokache, and Michael Seckl, and Philip Savage
Etoposide-induced hypersensitivity reactions. Report of two cases.
December 1985, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
Copied contents to your clipboard!